Going head-to-head with Eylea, Roche touts PhIII win for bispecific blockbuster contender in diabetic macular edema
Roche had its sights set on Eylea — the blockbuster eye drug that essentially made Regeneron — early in the development program for the bispecific antibody faricimab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
